CA3163777A1 - Combination immunotherapy of il-15 and cd40 agonist in cancer treatment - Google Patents

Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Info

Publication number
CA3163777A1
CA3163777A1 CA3163777A CA3163777A CA3163777A1 CA 3163777 A1 CA3163777 A1 CA 3163777A1 CA 3163777 A CA3163777 A CA 3163777A CA 3163777 A CA3163777 A CA 3163777A CA 3163777 A1 CA3163777 A1 CA 3163777A1
Authority
CA
Canada
Prior art keywords
agonist
dose
per
body weight
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3163777A
Other languages
English (en)
French (fr)
Inventor
Evelien Smits
Jonas VANAUDENAERDE
Marc Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Universiteit Antwerpen
Original Assignee
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Universiteit Antwerpen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIVERSITAIR ZIEKENHUIS ANTWERPEN, Universiteit Antwerpen filed Critical UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Publication of CA3163777A1 publication Critical patent/CA3163777A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3163777A 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment Pending CA3163777A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214049.9 2019-12-06
EP19214049 2019-12-06
PCT/EP2020/084665 WO2021110930A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Publications (1)

Publication Number Publication Date
CA3163777A1 true CA3163777A1 (en) 2021-06-10

Family

ID=68808124

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3163777A Pending CA3163777A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Country Status (8)

Country Link
US (1) US20220411524A1 (https=)
EP (1) EP4069739A1 (https=)
JP (1) JP2023505303A (https=)
CN (1) CN115052891A (https=)
AU (1) AU2020395907A1 (https=)
CA (1) CA3163777A1 (https=)
IL (1) IL293613A (https=)
WO (1) WO2021110930A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523181A (ja) * 2021-06-03 2024-06-28 アペクシジェン アメリカ， インコーポレイテッド Ｃｄ－４０アゴニストを用いてがんを処置する方法
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
IL293613A (en) 2022-08-01
US20220411524A1 (en) 2022-12-29
JP2023505303A (ja) 2023-02-08
WO2021110930A1 (en) 2021-06-10
EP4069739A1 (en) 2022-10-12
AU2020395907A1 (en) 2022-07-21
CN115052891A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
US11730803B2 (en) Cancer immunotherapy using virus particles
Jarosz-Biej et al. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
JP6416926B2 (ja) ガン標的化ｉｌ−１２免疫療法
US20220411524A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
CA3167386A1 (en) A bacterial composition for the treatment of cancer
US20230270861A1 (en) Inhibitors of the Artemin Pathway for Treatment of Cancer
Wang et al. Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model
Tang et al. Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice
US20240009275A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
Gong et al. Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy
US20200368324A1 (en) Preventing cytokine release syndrome
US20240010740A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
EP4621058A1 (en) Immunoenhancing salmonella strain for treatment of cancer and use thereof
EP4681707A1 (en) Method for treating diseases by using reparixin alone or in combination with anti-pd-1 antibody
HK40068065A (en) Cancer immunotherapy using virus particles
EP4615472A1 (en) Compositions and systems for combinatorial therapies containing fucosylated cells and immune checkpoint inhibitors and methods of production and use thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260115